The Geron Turnaround Could Start Next Quarter

by Biotech Newsroom


Word Count: 3,333 words, Reading Time: 15 minutes. Not financial advice, do your own due diligence, for entertainment purposes only.

Subscribers: Substack is telling me this post is too long for email so please load in browser if the bottom is cut off.

Last week, I spent a little time bragging about my good calls of 2025 and doing a summary of each one of my current “Tier 1” (a.k.a favorite) ideas:

One idea in there though I felt needed to be expanded further. That idea is Geron



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC